Patent intelligence · US
US 11154500
Solid solution compositions and use in chronic inflammation
Solid solution compositions and use in chronic inflammation
Patent details — US 11154500
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 26, 2021
- Expiration
- Oct 21, 2041
- Applicant
- Infirst Healthcare Limited
- Claims
- 20
- CPC classes
- A61K, A61K31/12, A61K31/137, A61K31/167
Quick answer
US 11154500 (Solid solution compositions and use in chronic inflammation) is held by Infirst Healthcare Limited. Status: granted. Granted Oct 26, 2021. Expires Oct 21, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Infirst Healthcare Limited
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/12, A61K31/137, A61K31/167, A61K31/19, A61K31/192
More from Infirst Healthcare Limited
Related pharmaceutical patents in our USPTO index.
-
US 12357666
Traditional Chinese herbal plant composition for improving symptoms of liver cancer patients and compatibility method thereof
granted -
US 12228572
Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
granted -
US 12220446
Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF
granted -
US 12090156
Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)
granted -
US 12076443
Preparation method of nanozyme composite-based hybrid hydrogel eye drop
granted -
US 12016950
Devices and methods for treating ear pain
granted -
US 11992555
Solid solution compositions and use in chronic inflammation
granted -
US 11980602
Cannabinoid prodrug compounds
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 11154500?
US 11154500 (Solid solution compositions and use in chronic inflammation) is held by Infirst Healthcare Limited. Status: granted. Granted Oct 26, 2021. Expires Oct 21, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11154500?
Infirst Healthcare Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 123 pharmaceutical patents for this assignee.
When does US 11154500 expire?
Our index shows an expiration date of Oct 21, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.